Evidence map›Paper›PMID 38867823›Full record

ArticlePCN reports : psychiatry and clinical neurosciences2023

Clinical practice for unspecified anxiety disorder in primary care.

Hitoshi Sakurai, Masahiro Takeshima, Ken Inada, Yumi Aoki, Kenya Ie, Morito Kise, Eriko Yoshida, Takashi Tsuboi, Hisashi Yamada, Hikaru Hori and 5 more

Abstract read
In one paragraph

Article in PCN reports : psychiatry and clinical neurosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical practice for unspecified anxiety disorder in primary care.PCN reports : psychiatry and clinical neurosciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hitoshi SakuraiDepartment of Neuropsychiatry Kyorin University Faculty of Medicine Tokyo Japan.ORCID 0000-0002-5399-7946
Masahiro TakeshimaDepartment of Neuropsychiatry Akita University Graduate School of Medicine Akita Japan.
Ken InadaDepartment of Psychiatry School of Medicine Kanagawa Japan.
Yumi AokiDepartment of Psychiatric and Mental Health Nursing St. Luke's International University Tokyo Japan.
Kenya IeDepartment of Internal Medicine Division of General Internal Medicine Kanagawa Japan.
Morito KiseCentre for Family Medicine Development Japanese Health and Welfare Co-Operative Federation Tokyo Japan.
Eriko YoshidaDepartment of General Internal Medicine Kawasaki Kyodo Hospital, Kawasaki Health Cooperative Association Kanagawa Japan.
Takashi TsuboiDepartment of Neuropsychiatry Kyorin University Faculty of Medicine Tokyo Japan.
Hisashi YamadaDepartment of Neuropsychiatry Hyogo Medicial University Hyogo Japan.
Hikaru HoriDepartment of Psychiatry, Faculty of Medicine Fukuoka University Fukuoka Japan.
Yasushi InadaMedical Corporation YUJIN-KAI Inada Clinic Osaka Japan.
Eiji ShimizuResearch Center for Child Mental Development Chiba University Chiba Japan.
Kazuo MishimaDepartment of Neuropsychiatry Akita University Graduate School of Medicine Akita Japan.
Koichiro WatanabeDepartment of Neuropsychiatry Kyorin University Faculty of Medicine Tokyo Japan.
Yoshikazu TakaesuDepartment of Neuropsychiatry Kyorin University Faculty of Medicine Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Clinicians face difficulties in making treatment decisions for unspecified anxiety disorder due to the absence of any treatment guidelines. The objective of this study was to investigate how familiar and how often primary care physicians use pharmacological and nonpharmacological approaches to manage the disorder. Methods: A survey was conducted among 117 primary care physicians in Japan who were asked to assess the familiarity of using each treatment option for unspecified anxiety disorder on a binary response scale (0 = "unfamiliar," 1 = "familiar") and the frequency on a nine-point Likert scale (1 = "never used," 9 = "frequently used"). Results: While several benzodiazepine anxiolytics were familiar to primary care physicians, the frequencies of prescribing them, including alprazolam (4.6 ± 2.6), ethyl loflazepate (3.6 ± 2.4), and clotiazepam (3.5 ± 2.3), were low. In contrast, certain nonpharmacological options, including lifestyle changes (5.4 ± 2.3), coping strategies (5.1 ± 2.7), and psychoeducation for anxiety (5.1 ± 2.7), were more commonly utilized, but to a modest extent. When a benzodiazepine anxiolytic drug failed to be effective, primary care physicians selected the following management strategies to a relatively high degree: differential diagnosis (6.4 ± 2.4), referral to a specialist hospital (5.9 ± 2.5), lifestyle changes (5.2 ± 2.5), and switching to selective serotonin reuptake inhibitor (5.1 ± 2.4). Conclusion: Primary care physicians exercise caution when prescribing benzodiazepine anxiolytics for unspecified anxiety disorder. Nonpharmacological interventions and switching to SSRI are modestly employed as primary treatment options and alternatives to benzodiazepine anxiolytics. To ensure the safe and effective treatment of unspecified anxiety disorder in primary care, more information should be provided from field experts.

Indexed as

anxiolyticsbenzodiazepineprimary careunspecified anxiety disorder

Identifiers

PMID38867823
PMCPMC11114420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.